Zobrazeno 1 - 10
of 41
pro vyhledávání: ''
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Pascale Tinguely, Simeon J.S. Ruiter, Jennie Engstrand, Robbert J. de Haas, Henrik Nilsson, Daniel Candinas, Koert P. de Jong, Jacob Freedman
Publikováno v:
Tinguely, Pascale; Ruiter, Simeon J S; Engstrand, Jennie; de Haas, Robbert J; Nilsson, Henrik; Candinas, Daniel; de Jong, Koert P; Freedman, Jacob (2023). A prospective multicentre trial on survival after Microwave Ablation VErsus Resection for Resectable Colorectal liver metastases (MAVERRIC). European journal of cancer, 187, pp. 65-76. Elsevier 10.1016/j.ejca.2023.03.038
AIM: This multi-centre prospective cohort study aimed to investigate non-inferiority in patients' overall survival when treating potentially resectable colorectal cancer liver metastasis (CRLM) with stereotactic microwave ablation (SMWA) as opposed t
Autor:
Van Not, Olivier J, van den Eertwegh, Alfons J M, Haanen, John B, van Rijn, Rozemarijn S, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Boers-Sonderen, Marye J, van Eijs, Mick J M, de Groot, Jan-Willem B, Hospers, Geke A P, Kapiteijn, Ellen, de Meza, Melissa, Piersma, Djura, Stevense-den Boer, Marion, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Wouters, Michel W J M, Suijkerbuijk, Karijn P M, Blokx, Willeke A M
Publikováno v:
European Journal of Cancer, 186, 27-37. Elsevier Ltd.
European Journal of Cancer, 186, 27-37
van Not, O J, van den Eertwegh, A J M, Haanen, J B, van Rijn, R S, Aarts, M J B, van den Berkmortel, F W P J, Blank, C U, Boers-Sonderen, M J, van Eijs, M J M, de Groot, J-W B, Hospers, G A P, Kapiteijn, E, de Meza, M, Piersma, D, Stevense-den Boer, M, van der Veldt, A A M, Vreugdenhil, G, Wouters, M W J M, Suijkerbuijk, K P M & Blokx, W A M 2023, ' Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies ', European Journal of Cancer, vol. 186, pp. 27-37 . https://doi.org/10.1016/j.ejca.2023.03.009
European Journal of Cancer, 186, 27-37. Pergamon
European Journal of Cancer, 186, 27-37. ELSEVIER SCI LTD
European Journal of Cancer, 186, pp. 27-37
European Journal of Cancer, 186, 27-37
van Not, O J, van den Eertwegh, A J M, Haanen, J B, van Rijn, R S, Aarts, M J B, van den Berkmortel, F W P J, Blank, C U, Boers-Sonderen, M J, van Eijs, M J M, de Groot, J-W B, Hospers, G A P, Kapiteijn, E, de Meza, M, Piersma, D, Stevense-den Boer, M, van der Veldt, A A M, Vreugdenhil, G, Wouters, M W J M, Suijkerbuijk, K P M & Blokx, W A M 2023, ' Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies ', European Journal of Cancer, vol. 186, pp. 27-37 . https://doi.org/10.1016/j.ejca.2023.03.009
European Journal of Cancer, 186, 27-37. Pergamon
European Journal of Cancer, 186, 27-37. ELSEVIER SCI LTD
European Journal of Cancer, 186, pp. 27-37
Background: Patients diagnosed with haematologic malignancies (HMs) have a higher risk of developing subsequent solid tumours, such as melanoma. Patients with HM were mostly excluded from clinical trials but potentially derive less benefit from immun
Autor:
Renu R. Bahadoer, Geke A.P. Hospers, Corrie A.M. Marijnen, Koen C.M.J. Peeters, Hein Putter, Esmée A. Dijkstra, Elma Meershoek-Klein Kranenbarg, Annet G.H. Roodvoets, Boudewijn van Etten, Per J. Nilsson, Bengt Glimelius, Cornelis J.H. van de Velde
Publikováno v:
European Journal of Cancer, 185, 139-149. ELSEVIER SCI LTD
INTRODUCTION: Although optimising rectal cancer treatment has reduced local recurrence rates, many patients develop distant metastases (DM). The current study investigated whether a total neoadjuvant treatment strategy influences the development, loc
Autor:
Meike W. Vernooij, Jacqueline J. Loonen, Marry M. van den Heuvel-Eibrink, Marloes Louwerens, Charlotte M. de Boer, Eline van Dulmen-den Broeder, Netteke Schouten-van Meeteren, Helena J H van der Pal, A. B. Versluys, Jop C Teepen, Jaap den Hartogh, Nynke Hollema, Andrica C H de Vries, Geert O. Janssens, Pieter Wesseling, L. C. M. Kremer, Lukas J.A. Stalpers, Judith L. Kok, Wim J. E. Tissing, Flora E. van Leeuwen, Margriet van der Heiden-van der Loo, Cécile M. Ronckers, Lisanne C Verbruggen, Eelco W. Hoving, Monique W. M. Jaspers, Sebastian J C M M Neggers
Publikováno v:
European Journal of Cancer, 150, 240-249
European Journal of Cancer, 150, pp. 240-249
European Journal of Cancer, 150, 240-249. Elsevier Ltd.
European Journal of Cancer, 150, 240-249. ELSEVIER SCI LTD
European Journal of Cancer, 150, pp. 240-249
European Journal of Cancer, 150, 240-249. Elsevier Ltd.
European Journal of Cancer, 150, 240-249. ELSEVIER SCI LTD
Background: Meningiomas are the most frequent brain tumours occurring after pediatric cranial radiotherapy (CrRT). Data on course of disease, to inform clinical management of meningiomas, are sparse. This study reports the clinical characteristics of
Autor:
Reinders, M.T.M., Meer, S. van, Burgmans, M.C., Jong, K.P. de, Klumpen, H.J., Man, R.A. de, Ramsoekh, D., Sprengers, D., Tjwa, E.T.T.L., Vos-Geelen, J. de, Erpecum, K.J. van, Geest, L.G.M. van der, Dutch Hepatocellular & Cholangioca
Publikováno v:
European Journal of Cancer, 137, 214-223
European Journal of Cancer, 137, 214-223. ELSEVIER SCI LTD
European Journal of Cancer, 137, 214-223. Elsevier Limited
European Journal of Cancer, 137, 214-223. Elsevier Ltd.
European Journal of Cancer, 137, 214-223. Pergamon
European Journal of Cancer, 137, pp. 214-223
Reinders, M T M, van Meer, S, Burgmans, M C, de Jong, K P, Klümpen, H J, de Man, R A, Ramsoekh, D, Sprengers, D, Tjwa, E T T L, de Vos-Geelen, J, van Erpecum, K J, van der Geest, L G M & Dutch Hepatocellular & Cholangiocarcinoma Group (DHCG) 2020, ' Trends in incidence, diagnosis, treatment and survival of hepatocellular carcinoma in a low-incidence country : Data from the Netherlands in the period 2009–2016 ', European Journal of Cancer, vol. 137, pp. 214-223 . https://doi.org/10.1016/j.ejca.2020.07.008
European Journal of Cancer, 137, 214-223. ELSEVIER SCI LTD
European Journal of Cancer, 137, 214-223. Elsevier Limited
European Journal of Cancer, 137, 214-223. Elsevier Ltd.
European Journal of Cancer, 137, 214-223. Pergamon
European Journal of Cancer, 137, pp. 214-223
Reinders, M T M, van Meer, S, Burgmans, M C, de Jong, K P, Klümpen, H J, de Man, R A, Ramsoekh, D, Sprengers, D, Tjwa, E T T L, de Vos-Geelen, J, van Erpecum, K J, van der Geest, L G M & Dutch Hepatocellular & Cholangiocarcinoma Group (DHCG) 2020, ' Trends in incidence, diagnosis, treatment and survival of hepatocellular carcinoma in a low-incidence country : Data from the Netherlands in the period 2009–2016 ', European Journal of Cancer, vol. 137, pp. 214-223 . https://doi.org/10.1016/j.ejca.2020.07.008
Objective: Evaluation of the trends in incidence, diagnostics, treatment and survival of patients with hepatocellular carcinoma (HCC) in the Netherlands.Method: Data regarding incidence, diagnostics, primary treatment and survival of patients with HC
Autor:
Steven G. Rozen, Heike I. Grabsch, Alvin Wei Tian Ng, William H. Allum, Wen Fong Ooi, Jimmy Bok Yan So, Wei Peng Yong, Patrick Tan, Ruth E Langley, Raghav Sundar, Vivien Koh, Ming Hui Lee, Lindsay C. Hewitt, David Cunningham, Matthew Nankivell, Nisha Padmanabhan, Taotao Sheng, Shenli Zhang, Aditi Qamra, Hermioni Zouridis, Imran Inam
Publikováno v:
European Journal of Cancer, 123, 48-57. ELSEVIER SCI LTD
Background: DNA methylation signatures describing distinct histological subtypes of oesophageal cancer have been reported. We studied DNA methylation in samples from the MRC OE02 phase III trial, which randomised patients with resectable oesophageal
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Piotr Rutkowski, Wilson H. Miller, Ivana Krajsová, Christian U. Blank, Paola Queirolo, Ana Arance, Paul Lorigan, Mario Mandalà, Geke A. P. Hospers, Bart Neyns, Jacob Schachter, Vanna Chiarion Sileni, James Larkin, Martina Makrutzki, Enrique Espinosa, Alexander Guminski, Margarita Donica, Axel Hauschild, Gabriela Liszkay, Marta Nyakas, Michele Del Vecchio, Paolo A. Ascierto, Claus Garbe, Helen Gogas, Michael P. Brown
Publikováno v:
European Journal of Cancer, 107, 175-185. ELSEVIER SCI LTD
BACKGROUND: The oncogenic BRAF inhibitor vemurafenib improves outcomes for patients with advanced BRAFV600 mutation-positive melanoma compared with cytotoxic chemotherapy. Vemurafenib is now approved for use in this patient population.PATIENTS AND ME